Ongoing Clinical Trials for Prolactin-producing Pituitary Tumour
Currently, there is 1 ongoing clinical trial for patients with prolactin-producing pituitary tumours, specifically focusing on microprolactinomas. This trial is being conducted in Italy and compares surgical treatment with standard medication therapy for newly diagnosed patients. The study aims to help doctors understand which treatment approach works best in controlling hormone levels and reducing tumour size.
Clinical trial locations
Comparison of Surgical Treatment versus Cabergoline in Patients with Newly Diagnosed Microprolactinomas
This clinical trial focuses on microprolactinomas, which are small benign tumours that develop in the pituitary gland and produce excess amounts of the hormone prolactin. These tumours are typically less than 10 millimeters in size and can cause various symptoms including irregular menstrual periods and milk production in women who are not pregnant or nursing, while in men they can cause reduced sex drive and fertility issues.
Main inclusion criteria: To participate in this study, you must be between 18 and 65 years old and have a newly diagnosed microprolactinoma confirmed by MRI scan, with a maximum tumour size of 10 millimeters. You need to have elevated prolactin levels confirmed by at least 2 separate blood tests, along with symptoms suggesting high prolactin levels. Importantly, you must not have received any previous treatment for high prolactin levels, including medications, surgery, or radiation therapy. You should be able to understand the study’s purpose and complete questionnaires independently.
Main exclusion criteria: You cannot participate if you are under 18 or over 65 years old, are currently pregnant or breastfeeding, or have previously received treatment for microprolactinoma. The study also excludes patients with other hormonal disorders, severe liver or kidney disease, uncontrolled high blood pressure, history of heart disease or abnormal heart rhythm, or active psychiatric conditions requiring medication. If you have a known allergy to the study medications, a history of drug or alcohol abuse within the past year, or are currently participating in other clinical trials, you will not be eligible.
Focus and goals: The research compares two different treatment approaches: surgical removal of the tumour through endoscopic endonasal surgery and medical treatment with cabergoline. The study aims to determine if surgical treatment works as well as the standard medical treatment in controlling hormone levels and reducing tumour size. Patients will be monitored for up to 12 months, with evaluations at 6 months and 12 months including blood tests to measure prolactin levels and MRI scans to assess tumour size.
Investigational treatments: The trial compares two approaches. Cabergoline is a medication taken orally in tablet form, belonging to a group of drugs called dopamine agonists. It works by reducing prolactin production in the brain and has become the standard medical treatment for prolactinomas. The medication is given at a maximum daily dose of 0.5 milligrams for up to 12 months. Endoscopic endonasal surgery is a minimally invasive surgical procedure where doctors access and remove the tumour through the nose without making any external cuts. This technique allows surgeons to reach the tumour at the base of the brain through the nasal passages, offering an alternative to medication-based treatment.
Summary
Currently, only one clinical trial is actively recruiting patients with prolactin-producing pituitary tumours, specifically those with microprolactinomas. This trial is being conducted in Italy and represents an important study comparing surgical intervention with standard medical therapy. The research is particularly valuable for newly diagnosed patients as it may help establish which treatment approach provides the best outcomes in terms of hormone control and tumour reduction. The trial focuses on comparing cabergoline, which has been the standard first-line treatment for many years, with endoscopic endonasal surgery, a minimally invasive surgical approach. Patients interested in participating should note the specific age requirements and the need to be treatment-naive, meaning they have not received any prior therapy for their condition.
